about
Genetic analysis of a poliovirus/hepatitis C virus (HCV) chimera: interaction between the poliovirus cloverleaf and a sequence in the HCV 5' nontranslated region results in a replication phenotypeHCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasmaIdentification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B proteinKinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined ExperimentallyThe Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5AInterim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection
P50
Q27469671-4D3C10CD-37B7-448F-8D6F-24B47B909AF5Q28545256-158E2574-832F-44D7-8800-ED9E825822C2Q30418339-D7711E6C-EFD8-4BA4-97B8-BB52A5947B25Q33934312-9C7524F2-01F1-483A-84DE-0C57F1D87FD7Q40239514-E1BA5F9D-1FEF-4A12-88FC-0B469B5E96BBQ40543016-F1233604-6295-4F08-9B8B-71DF3E701A21Q40773451-E2953521-CACE-4932-B337-0A634E104EC2Q42174310-68E3D975-63B7-4C6A-A192-27809CB41323Q42253772-393B6205-5270-43D6-9558-2E4E4EB286C3Q42711188-D526A65B-0EBA-4A45-AFF5-D929C092208DQ42989695-C2CF1B34-84A8-4E1F-93D0-CCA0BB4B619BQ57789733-147573D9-D042-4FEF-8A67-2711C25B4868Q90426583-8016EA96-72F7-4219-9587-CD6E0D188E6B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fred Lahser
@ast
Fred Lahser
@en
Fred Lahser
@es
Fred Lahser
@nl
type
label
Fred Lahser
@ast
Fred Lahser
@en
Fred Lahser
@es
Fred Lahser
@nl
prefLabel
Fred Lahser
@ast
Fred Lahser
@en
Fred Lahser
@es
Fred Lahser
@nl
P106
P31
P496
0000-0003-4902-0435